IPP Bureau
Novavax to participate in two booster studies using its COVID-19 vaccine
By IPP Bureau - March 26, 2022
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
Fujifilm India unveils new range of CT, MRI and ultrasound machines
By IPP Bureau - March 26, 2022
The enhanced portfolio includes the Scenaria View, Supria series, The Echelon Smart and Arietta series
Evusheld recommended for market authorisation in EU
By IPP Bureau - March 25, 2022
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Leadership changes at MedGenome
By IPP Bureau - March 25, 2022
Co–Founder Sam Santhosh steps down as Chairman and Group CEO; will remain on Board of Directors. Co–founder Mahesh Pratapneni appointed Group CEO. Dr. Felix Olale appointed Chairman of the Board
Aquavit Files IND with USFDA for DTX-021, a new botulinum toxin
By IPP Bureau - March 25, 2022
Aquavit will officially unveil the Dermatox and Microtox programs at the Annual American Academy of Dermatology, the world's largest dermatology conference scheduled from March 25-29, 2022, in Boston, MA
USFDA approves Janssen’s injectable regimen for HIV
By IPP Bureau - March 25, 2022
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
Parata Systems earns HITRUST certification
By IPP Bureau - March 25, 2022
It recognizes the company's commitment to safeguarding sensitive data, protecting patient information
Medtronic announces first patient implants for bladder incontinence
By IPP Bureau - March 25, 2022
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
Roche to present data across neuroscience portfolio at 2022 AAN Annual Meeting
By IPP Bureau - March 25, 2022
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Bar Ilan University launches course on 3D printing in medicine
By IPP Bureau - March 25, 2022
A new course at the Azrieli Faculty of Medicine will focus on tissue regeneration and 3D printing for therapeutic needs
BSV standardises on Veeva Vault PromoMats to speed content distribution
By IPP Bureau - March 25, 2022
Vault PromoMats helps life sciences companies speed the creation, review, and distribution of compliant content. Built-in digital asset management enables content reuse and reduces spend on promotional materials
PHARMAP 2022 to discuss contemporary issues
By IPP Bureau - March 25, 2022
The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies
CHMP recommends EU approval of Roche’s new combination treatment for large B-cell lymphoma
By IPP Bureau - March 25, 2022
Recommendation is based on pivotal data from the phase III POLARIX study
Japan approves BMS’ Breyanzi application for relapsed large B-cell lymphoma
By IPP Bureau - March 25, 2022
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
SRL Diagnostics launches whole genome sequencing test for Tuberculosis
By IPP Bureau - March 24, 2022
The test can overcome the time and cost limitations of traditional culture-based drug susceptibility testing as it can more rapidly detect all mutations known to be associated with drug resistance for any TB drug in one step
